RCEL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Based on the data provided, AVITA Medical Inc (RCEL) is not a strong buy for a beginner, long-term investor at this moment. The stock shows no significant positive catalysts, has declining financial performance, and lacks strong technical or proprietary trading signals to support a buy decision. It is better to hold off on investing until there is more clarity on business stabilization or stronger indicators of growth.
The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 68.557, and moving averages are converging, showing no clear trend. The stock is currently trading near the pivot level of 4.681, with resistance at 5.597 and support at 3.764.
Hedge funds have significantly increased their buying activity by 534.61% over the last quarter.
Revenue dropped by -4.30% YoY in Q4 2025, and EPS declined by -13.64% YoY. Gross margin also decreased by -6.97% YoY. Analysts maintain a Hold rating, citing the need for business stabilization. No recent news or congress trading data to support a positive sentiment.
In Q4 2025, revenue decreased to $17.615 million (-4.30% YoY), net income improved slightly to -$11.621 million (+0.28% YoY), EPS dropped to -0.38 (-13.64% YoY), and gross margin declined to 81.9% (-6.97% YoY).
Lake Street raised the price target to $3.50 from $3 but maintained a Hold rating, citing the need for business stabilization and incremental confidence from Q4 results and reimbursement trends.
